OraSure Sees Profitability In 2002 With OraQuick, UPlink Introductions
This article was originally published in The Gray Sheet
OraSure Technologies expects FDA approvals of its UPlink drugs-of-abuse test and OraQuick rapid HIV assay to help the firm reach profitability this year and grow revenues 30% over 2001
You may also be interested in...
Point-of-care oral fluid opiate detector test system gains 510(k) clearance on April 5. Development of a five-panel oral fluid assay for cocaine, methamphetamine/amphetamine, PCP and marijuana is ongoing; OraSure plans to submit a 510(k) for the indication by mid-summer ("1The Gray Sheet" Jan. 28, 2002, p. 4)...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.